QPPV.COM KNOWLEDGE ASSESSMENT

Proton Pump Inhibitors and Hypomagnesaemia: A Signal Evaluation

Test your understanding of the concepts covered by Proton Pump Inhibitors and Hypomagnesaemia: A Signal Evaluation.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which sequence provides the strongest individual-case evidence for a causal relationship between a PPI and hypomagnesaemia?

PPI exposure followed by low magnesium, without further follow-up Low magnesium before PPI initiation followed by continued low magnesium PPI exposure, hypomagnesaemia, recovery after withdrawal, and recurrence after re-exposure PPI exposure accompanied by a nonspecific gastrointestinal symptom

Question 2 of 10 A safety professional sees one report of mild hypomagnesaemia in a PPI user with chronic diarrhoea and thiazide therapy. What is the most appropriate initial interpretation?

The PPI is definitely causal because hypomagnesaemia is a recognised signal The case is uninterpretable and should be discarded The case requires careful assessment of competing causes and clinical chronology before its causal weight is judged The case proves that thiazides do not contribute to magnesium loss

Question 3 of 10 What is the most appropriate interpretation of reports involving omeprazole, esomeprazole, pantoprazole and rabeprazole?

They support consideration of a class effect They prove that all PPIs have identical potency and risk They demonstrate that the reaction is caused by a manufacturing impurity common to all products They show that duration of treatment is irrelevant

Question 4 of 10 Which approach best reflects appropriate signal evaluation for this association?

Rely exclusively on the pooled relative risk from one meta-analysis Rely exclusively on the number of spontaneous reports Integrate individual cases, physiology, dechallenge, rechallenge, class consistency, epidemiology and mechanism Disregard mechanistic and clinical information because the event is a laboratory abnormality

Question 5 of 10 Which statement best represents a layered pharmacovigilance conclusion for PPI-associated hypomagnesaemia?

PPIs cause hypomagnesaemia in all users through a fully proven molecular pathway There is no causal association because the incidence and susceptibility factors are uncertain PPIs can cause clinically important hypomagnesaemia in susceptible patients, while incidence, susceptibility factors and precise mechanism remain incompletely defined Only the epidemiological association is established; individual cases provide no additional evidence

Question 6 of 10 Which factor is a potential confounder when comparing hypomagnesaemia in PPI users with non-users?

Use of diuretics and greater burden of comorbidity among PPI users The fact that magnesium is measured in serum The existence of a product information document The use of a non-proprietary drug name

Question 7 of 10 Which counterfactual observation would most weaken the proposed causal association?

Some cases occur after several years of exposure Cases include concomitant diuretic use There is no consistent improvement after withdrawal and no recurrence after re-exposure across well-documented cases Different observational studies use different definitions of hypomagnesaemia

Question 8 of 10 Which statement best reflects the relationship between causal assessment and mechanistic certainty?

Causality cannot be accepted until one molecular pathway is proven in every patient A clinically important causal association may be supported even when the complete molecular mechanism remains uncertain Mechanistic uncertainty disproves all positive dechallenge observations Mechanistic plausibility is unnecessary when epidemiological heterogeneity is present

Question 9 of 10 What is the most defensible conclusion from repeated recurrence of hypomagnesaemia after switching between different PPIs?

The event is unrelated to PPIs because different products were involved The pattern supports a class effect, while not proving identical risk for every PPI Only the second PPI can be considered causal The recurrence proves a specific TRPM6 mutation in the patient

Question 10 of 10 Why can this signal merit substantial pharmacovigilance attention even if clinically significant cases are uncommon?

Rare events are always more causal than common events PPIs are widely used and the event may be serious, difficult to recognise and reversible after withdrawal Any laboratory abnormality automatically requires regulatory action Uncommon events do not require assessment of benefit-risk balance

Proton Pump Inhibitors and Hypomagnesaemia: A Signal Evaluation

Cookie Settings